Follicular Challenge Test to Predict Response to GnRH Agonist Triggering

Assaf-Harofeh Medical Center100 enrolled

Overview

GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or suboptimal response was displayed. The investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.

The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist protocol. Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the hormonal profile will be compared to day after ovulation triggering.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

100

Conditions

Infertility, Female

Interventions

DecapeptylOTHER

diagnosis of predictio value

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 41 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients that undergo fertility preservation * patients planned to freeze embryos due to PGT or surrogacy --patients at high risk for OHSS Exclusion Criteria: * Poor ovarian response * known hypothalamic- pituitary dysfunction

Locations (1)

Shamir medical center

Tzrifin, Israel

RECRUITING

Outcomes

Primary Outcomes

The response to GnRH triggering

LH levels 10-12 hours after decapeptyl trigger, number of mature oocytes

Time frame: One treatment cycle (each cycle is 28 days) for each participant (up to 28 days).

Central Contacts

Sarit Avraham, Dr

CONTACT

00972522371126 sarita@shamir.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.